ES2156293T3 - Metodo para producir vasodilatacion con derivados de (1,5-inter)arilprostaglandina. - Google Patents

Metodo para producir vasodilatacion con derivados de (1,5-inter)arilprostaglandina.

Info

Publication number
ES2156293T3
ES2156293T3 ES96931432T ES96931432T ES2156293T3 ES 2156293 T3 ES2156293 T3 ES 2156293T3 ES 96931432 T ES96931432 T ES 96931432T ES 96931432 T ES96931432 T ES 96931432T ES 2156293 T3 ES2156293 T3 ES 2156293T3
Authority
ES
Spain
Prior art keywords
sub
presents
carbon atoms
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96931432T
Other languages
English (en)
Inventor
June Chen
Robert M Burk
David F Woodward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Application granted granted Critical
Publication of ES2156293T3 publication Critical patent/ES2156293T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE UN PROCEDIMIENTO PARA LLEVAR A CABO LA VASODILATACION, QUE INCLUYE: ADMINISTRAR A UN ANIMAL DE SANGRE CALIENTE QUE NECESITE TAL TRATAMIENTO UNA CANTIDAD EFICAZ DE UN DERIVADO DE (1,5 PRESENTADO POR LA FORMULA (I), EN LA CUAL N ES 0 O UN NUMERO ENTERO DE 1 A 6, R SE SELECCIONA ENTRE EL GRUPO DE RADICALES REPRESENTADOS POR LAS FORMULAS: CO SUB,2}R , CONR SUB,2}, CH SUB,2}OR Y SO SUB,2}NR SUB,2}, EN LAS CUALES R ES HIDROGENO O UN RADICAL ALQUILO INFERIOR QUE PRESENTA DE UNO A SEIS ATOMOS DE CARBONO; R ES HIDROGENO O UN RADICAL ACILO QUE PRESENTA LA FORMULA: (CO)R , EN LA CUAL R ES UN RADICAL HIDROCARBURO ACICLICO SATURADO O INSATURADO QUE PRESENTA DE 1 A APROXIMADAMENTE 10 ATOMOS DE CARBONO, O O UN NUMERO ENTERO DE 1 A 6, Y R ES UN ANILLO ALIFATICO QUE PRESENTA DE 3 A 7 ATOMOS DE CARBONO O UN GRUPO ARILO, POR EJEMPLO FENILO, O UN GRUPO HETEROARILO, POR EJEMPLO TIENILO, FURANILO O PIRIDILO, Y PREFERIBLEMENTE R ES UN GRUPO ALQUILO INFERIOR QUE PRESENTA DE 1 A 6 ATOMOS DE CARBONO; LOS SEGMENTOS TRIANGULARES SOMBREADOS REPRESENTAN ENLACES CON ORIENTACION ALFA, LOS SEGMENTOS TRIANGULARES NEGROS REPRESENTAN ENLACES CON ORIENTACION BETA Y LOS SEGMENTOS ONDULADOS REPRESENTAN ENLACES QUE PUEDEN PRESENTAR UNA ORIENTACION CIS O TRANS. MAS PREFERIBLEMENTE, DICHO DERIVADO DE (1,5 ESTO REPRESENTADO POR LA FORMULA (II). LO MAS PREFERIBLE ES QUE DICHO DERIVADO DE (1,5 ESTO DE FORMULA (II) EN LA CUAL R ES CO SUB,2}R , R ES HIDROGENO Y N ES 0.
ES96931432T 1995-09-01 1996-08-28 Metodo para producir vasodilatacion con derivados de (1,5-inter)arilprostaglandina. Expired - Lifetime ES2156293T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/522,775 US5661178A (en) 1995-09-01 1995-09-01 Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives

Publications (1)

Publication Number Publication Date
ES2156293T3 true ES2156293T3 (es) 2001-06-16

Family

ID=24082299

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96931432T Expired - Lifetime ES2156293T3 (es) 1995-09-01 1996-08-28 Metodo para producir vasodilatacion con derivados de (1,5-inter)arilprostaglandina.

Country Status (8)

Country Link
US (2) US5661178A (es)
EP (1) EP0847276B1 (es)
JP (1) JP2000512262A (es)
AU (1) AU701835B2 (es)
CA (1) CA2230687A1 (es)
DE (1) DE69612006T2 (es)
ES (1) ES2156293T3 (es)
WO (1) WO1997009049A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191320A1 (en) * 1998-12-10 2007-08-16 Nexmed Holdings, Inc. Methods of treatment for female sexual arousal disorder
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US7511168B2 (en) * 2006-01-18 2009-03-31 Shih-Yi Wei Processes and intermediates for the preparations of prostaglandins
EP1810967B1 (en) * 2006-01-18 2014-07-30 Chirogate International Inc. Processes and intermediates for the preparations of prostaglandins

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3944595A (en) * 1972-10-30 1976-03-16 The Upjohn Company PGF1.sub.α -oxaphenylene compounds
US4048058A (en) * 1975-08-13 1977-09-13 Standard Oil Company (Indiana) Methods to be used in reforming processes employing multi-metallic catalysts
US4312810A (en) * 1978-11-22 1982-01-26 The Upjohn Company 2,5-Inter-o-phenylene-3,4-dinor-5,9α-epoxy-9-deoxy-PGF1 compounds
AU541825B2 (en) * 1978-11-22 1985-01-24 Upjohn Company, The Prostacyclin intermediate
IL65387A0 (en) * 1981-04-14 1982-05-31 Chinoin Gyogyszer Es Vegyeszet 2,3,4-trinor-m-inter-phenylene-prostaglandin derivatives and a process for the preparation thereof
US5306729A (en) * 1992-02-25 1994-04-26 Joslin Diabetes Center Method for effecting vasodilation with monoglycerides

Also Published As

Publication number Publication date
EP0847276B1 (en) 2001-03-07
US5750784A (en) 1998-05-12
WO1997009049A3 (en) 1997-07-10
JP2000512262A (ja) 2000-09-19
EP0847276A2 (en) 1998-06-17
US5661178A (en) 1997-08-26
DE69612006D1 (de) 2001-04-12
CA2230687A1 (en) 1997-03-13
AU701835B2 (en) 1999-02-04
AU7011396A (en) 1997-03-27
DE69612006T2 (de) 2001-08-23
WO1997009049A2 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
MX9203385A (es) Derivados de taxol y composiciones farmaceuticas que los contienen.
ES2157424T3 (es) Esteres de acido 5-aminolevulinico como agentes fotosensibilizantes en fotoquimioterapia.
ES2058040T3 (es) Colorante para teñir el cabello con un contenido en derivados del amino-pirazol y nuevos derivados del pirazol.
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
ES2137628T3 (es) Derivados de estilbeno y composiciones farmaceuticas que los contienen.
CO4290356A1 (es) Derivados de 1-aminoetilindol
ES2065936T3 (es) Procedimiento e intermedios para la preparacion de bis(aminoalquil)polidiorganosiloxanos.
ES2156293T3 (es) Metodo para producir vasodilatacion con derivados de (1,5-inter)arilprostaglandina.
AR005431A1 (es) Ozocolorantes reactivos con componentes de copulacion de la serie de los acidos aminonaftalensulfonicos, naftilaminas utilizadas y productos intermediosformados, en la preparacion de dichos ozocolorantes y utilizacion de los ozocolorantes.
AR003639A1 (es) Mezclas herbicidas sinergicas que contienen eteres de oxima de ciclohexenona, composiciones herbicidas formuladas con dichas mezclas, procedimiento para preparar dichas composiciones y metodo para combatir el crecimiento de plantas indeseables
MX9304524A (es) Nuevos derivados de indol y composiciones que los contienen.
ES2081697T3 (es) Composicion cosmetica reductora para la deformacion permanente de los cabellos a base de una mercaptoalquilaminoamida y procedimiento de deformacion permanente de los cabellos.
ES2159345T3 (es) Indazolcarboxamidas.
AR001838A1 (es) Derivados de azacicloal canos utiles para el tratamiento de la obesidad diabetes e hiperglucemia procedimiento para prepararlos composiciones farmacéuticas que los contienen y aplicación de dichos derivados en la preparación de dichas composiciones
ES2059931T3 (es) Procedimiento para el tratamiento de la hipertrofia e hiperplasia cardiaca asi como vascular.
ES2054650T3 (es) Fenilacetonitrilos basicamente substituidos, su obtencion y medicamentos que los contienen.
DE69108408D1 (de) 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.
ES2195089T3 (es) Benzotiofenos amorfos, procedimientos de preparacion y uso.
ES2104987T3 (es) Derivados de eteres milbemicina, su preparacion y su aplicacion terapeutica y agroquimica.
ES2131784T3 (es) Maquinilla jacquard del tipo de correas.
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
ES2176910T3 (es) Aditivo para masticacion de caucho natural, metodo de masticacion, composicion obtenida del mismo y cubierta neumatica.
AR003977A1 (es) Composiciones endoparasiticidas a base de didepsipeptidos, nuevos didepsipeptidos y procedimientos para su produccion.
MX9300008A (es) Nucleosidos terapeuticos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 847276

Country of ref document: ES